Physicochemical Properties
Molecular Formula | C23H29CL2N3O |
Molecular Weight | 434.4018638134 |
Exact Mass | 433.17 |
CAS # | 157000-76-5 |
Related CAS # | Datelliptium chloride;105118-14-7 |
PubChem CID | 24844807 |
Appearance | Typically exists as solid at room temperature |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 5 |
Heavy Atom Count | 29 |
Complexity | 496 |
Defined Atom Stereocenter Count | 0 |
InChi Key | QLZIAISICLKYOX-UHFFFAOYSA-N |
InChi Code | InChI=1S/C23H27N3O.2ClH/c1-5-25(6-2)11-12-26-10-9-18-16(4)23-22(15(3)20(18)14-26)19-13-17(27)7-8-21(19)24-23;;/h7-10,13-14,27H,5-6,11-12H2,1-4H3;2*1H |
Chemical Name | 2-[2-(diethylamino)ethyl]-5,11-dimethyl-6H-pyrido[4,3-b]carbazol-2-ium-9-ol;chloride;hydrochloride |
Synonyms | Datelliptium chloride hydrochloride |
HS Tariff Code | 2934.99.9001 |
Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
ln Vitro | In suspension and primary cultures of rat hepatocytes, datelliptium chloride hydrochloride exhibits cytotoxic effects after two hours of treatment[1]. |
ln Vivo | In vivo, datelliptium chloride hydrochloride exhibits extensive anticancer efficacy against mice's solid tumors[2]. When a disease is in its early stages, datelliptium chloride hydrochloride (170 mg/kg; IV; for 12 days) has a strong antitumor effect[2]. For solid tumors above leukemia L1210, hydrochloride is specifically cytotoxic[2]. |
Cell Assay | Cytotoxicity is measured using cultured and suspended rat hepatocytes following a brief (2-hour) exposure to datelliptium. In order to assess cytotoxicity following extended exposure, the compound is added one hour after cell plating and incubated for twenty-three hours using rat and human monolayers as well as hepatoma cell lines. In cultured cells, the endpoints assessed are the decrease in intracellular LDH and the MTT test. A colorimetric technique is used to measure the intracellular LDH in the microwell culture plates. The MTT test is carried out according to instructions, with the tetrazolium salt MTT being reduced to formazan by mitochondrial succinate dehydrogenase. Following a two-hour drug treatment, LDH leakage to the medium is used to assess cytotoxicity in the hepatocyte suspension. |
Animal Protocol |
Animal/Disease Models: Mice, colon adenocarcinoma early staged disease model[2] Doses: 170 mg/ kg Route of Administration: intravenous (iv)injection, for 12 days Experimental Results: demonstrated potent activity against colon adenocarcinoma. |
References |
[1]. Toxicity of the antitumoral drug datelliptium in hepatic cells: Use of models in vitro for the prediction of toxicity in vivo. Toxicol In Vitro. 1992 Jul;6(4):295-302. [2]. Activity of datelliptium acetate (NSC 311152; SR 95156A) against solid tumors of mice. Invest New Drugs. 1990 Aug;8(3):253-61. |
Solubility Data
Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10: 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300:Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.3020 mL | 11.5101 mL | 23.0203 mL | |
5 mM | 0.4604 mL | 2.3020 mL | 4.6041 mL | |
10 mM | 0.2302 mL | 1.1510 mL | 2.3020 mL |